Floatz logo

Carboplatin

Carcinoma, Adenosquamous

PfizerSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Carcinoma, Adenosquamous cohort.

Asset / SponsorPhaseRating
e7 tcr-t cells
Christian Hinrichs
Phase 2B
cp-751,871
Pfizer
Phase 3CCC
Tsc-202-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-204-A0101
TScan Therapeutics, Inc.
Phase 1CC
Tsc-201-B0702
TScan Therapeutics, Inc.
Phase 1CC

View all 9 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →